Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Krka increases half-year sales by 6.7% and confirms annual forecast
Krka reports H1 2026 sales growth of 6.7% to €1,113.8 million and an EBITDA margin of 31.9% (H1 2025: 28.9%). EBIT rose 20% to €309 million with a margin of 27.6%, and net profit climbed to €260 million (+5%). Five of six regions recorded growth; Eastern Europe remains the largest region with €405.2 million (+9%). The company confirms its 2026 targets: around €2,144 million in sales and a net profit of approximately €405 million. » Mere på de.investing.com
Krka posts record revenue and operating profit in Q1 2026
Krka reports record revenue of €566 million in Q1 2026 (+8%) and an operating profit of €152 million (+24%), with an EBITDA margin of 31%—one of the highest levels in the company’s history. Net profit fell to €121 million (−21% versus Q1 2025) due to a strong year‑ago comparison. Management highlights growth from product-portfolio expansion, strong cash flows and a proposed quarterly dividend of €9.1 per share; risks remain currency fluctuations, supply-chain issues and competitive pressure. » Mere på de.investing.com
Krka posts over €2 billion in revenue for first time after strong Q4 2026
The Krka Group reported 2026 revenue of €2.041 billion, up 7% year-on-year, marking the first time in the company’s history it exceeded €2 billion. Net profit rose 13% to €401 million, EBITDA was €560 million (EBITDA margin 27.4%). In 2025 Krka launched seventeen new products, is focusing on chronic diseases and expanding in heart failure and obesity, and plans joint ventures in China and India. For 2026 the company forecasts revenue of €2.144 billion and plans to invest €140 million; the share price reacted with a 1.04% increase. » Mere på de.investing.com
Krka achieves annual revenue above €2 billion for first time after strong quarter
The Krka Group reports revenue of €2.041 billion (+7%) and net profit of €401 million (+13%) for the 2026 fiscal year, with earnings per share of €13.14. EBITDA amounted to €560 million with a margin of 27.4%. The share rose 2.36% to €954. For 2026, Krka expects revenue of €2.144 billion (+5%) and plans investments of €140 million for further expansion. » Mere på de.investing.com
Krka raises 2025 net profit forecast and cuts capex plan
After strong nine-month results, Krka raised its 2025 net profit forecast from €365 million to around €383 million, while keeping its revenue forecast unchanged. At the same time, the company reduced planned capital expenditures for 2025 from €150 million to about €95 million. In the first nine months, revenue rose to €1.534 billion (+6.9%) and net profit to €323 million (+15.1%); Krka attributes the growth in part to ruble appreciation, an improved product mix and economies of scale. For 2026, Krka expects revenue of around €2.132 billion and net profit of about €405 million, and plans higher capex of €140 million to modernize capacities. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 554,74 mio. | 5,38 % |
| Bruttofortjeneste | 340,98 mio. | 12,55 % |
| Nettoresultat | 139,61 mio. | 49,05 % |
| EBITDA | 180,66 mio. | 26,21 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 7,6 mia. € |
Antal aktier | 30,28 mio. |
Højeste/laveste i 52 uger | 272,38 € - 183,86 € |
Udbytteafkast | 3,61 % |
Udbytte TTM | 9,10 € |
Beta | 0,46 |
P/E (PE Ratio) | 18,57 |
PEG (PEG Ratio) | 2,10 |
K/I (PB Ratio) | 2,91 |
P/S (PS Ratio) | 3,59 |
Virksomhedsprofil
Krka, d. d., et generisk farmaceutisk selskab, udvikler, producerer, markedsfører og sælger receptpligtige lægemidler, håndkøbsprodukter og produkter til dyresundhed i Slovenien, Sydøsteuropa, Østeuropa, Centraleuropa, Vesteuropa og internationalt. Dets receptpligtige lægemidler omfatter medicin til behandling af kardiovaskulære sygdomme; mave-tarmkanalen; centralnervesystemet; smertelindring; anti-infektiva; blod og bloddannende organer; urologiske lidelser; diabetes; og onkologi. Selskabet tilbyder også håndkøbsprodukter, såsom produkter til mundhule og svælg; hoste- og forkølelsesprodukter; analgetika; næseprodukter; vitamin- og mineralprodukter; produkter til forbedring af cerebral og perifer cirkulation; produkter til forbedring af fordøjelseskanalen og fordøjelsen; sundhedsplejeprodukter; og andre. Derudover tilbyder virksomheden produkter til dyresundhed, der omfatter antiinfektiva, antiparasitære midler og andre produkter til landbrugsdyr og selskabsdyr. Endvidere leverer selskabet sundheds- og turistydelser på kurbade. Krka, d. d. blev grundlagt i 1954 og har hovedkontor i Novo Mesto, Slovenien.
| Navn | Krka d.d. |
| CEO | Jože Colarič |
| Hjemsted | Novo Mesto,
nm Slovenien |
| Websted | |
| Sektor | Sundhed |
| Branche | Lægemidler |
| Børsnotering | 11.04.2012 |
| Medarbejdere | 13.236 |
Tickersymboler
| Børs | Symbol |
|---|---|
Wse | KRK.WA |
London | 0HLK.L |
Warschau | KRK.WA |